

Special Issue

Individualized Antithrombotic Risk Assessment & Therapy

Message from the Guest Editors

One of the key challenges in the management of thrombotic and cardiovascular diseases is the need to carefully balance bleeding and thrombotic risk. This equilibrium is physiologically maintained by the careful counter-balancing of procoagulant and anticoagulant proteins and is in close relation with the endothelium and vessel flow. This homeostasis can be disrupted by a variety of pathophysiological events, resulting in thrombotic and cardiovascular diseases as well as bleeding. The management of anticoagulation and antiplatelet therapies in these conditions requires the careful identification of high-risk individuals and the individualisation of therapy to optimise anti-thrombotic effects while minimising bleeding complications. The aim of this Special Issue is to explore the safety of current therapies as well as the ability of clinical risk assessment models and available diagnostic markers to effectuate an individualised approach for the prevention and treatment of thrombotic and cardiovascular diseases.

Guest Editors

Dr. Prahlad Ho

1. Department of Haematology, Northern Health, Epping, VIC 3076, Australia
2. Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
3. Department of Medicine, Northern Health, University of Melbourne, Heidelberg, Australia

Dr. Amir Houshang Shemirani

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Deadline for manuscript submissions

closed (20 April 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/105241

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).